Company Overview
| Stock Name | JXR |
|---|---|
| Stock Code | 01951 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 中美領先的輔助生殖服務供應商,主要提供輔助生殖服務、管理服務及輔助醫療服務。擁有及經營成都西囡婦科醫院及深圳中山泌尿外科醫院,共同管理錦江生殖中心,並管理美國HRC Medical。 |
| Listing Date | 2019-06-25 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國四川省成都市錦江區靜沙北路301號 |
| Business Address (Hong Kong) | 香港銅鑼灣勿地臣街1號時代廣場二座31樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.jxr-fertility.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 8.54 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | RMB 1e-05 / shares |
| Offer Period | 2019-06-13 to 2019-06-18 |
| Global Offering Shares | 357,124,000 shares |
| HK Public Offer Shares (Initial) | 35,716,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 321,408,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 2,380,815,802 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 38.5% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 3,049,838,960 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 5.99B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣212.1百萬元 |
| Period-End Cash Balance | 人民幣1,184.2百萬元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2016 |
|---|---|
| Revenue | 56,595 |
| Cost of sales | -40,378 |
| Gross profit | 16,217 |
| Other income and gains, net | 4 |
| Administrative expenses | -3,379 |
| Operating profit | 12,842 |
| Net finance costs | -75 |
| Profit before tax | 12,767 |
| Income tax expense | 0 |
| Profit for the year | 12,767 |
Balance Sheet
| Item | 2016 | 2017-07 |
|---|---|---|
| Cash and cash equivalents | 4,835 | |
| Trade and bills receivables | 7,063 | |
| Total current assets | 11,898 | |
| Total current liabilities | 7,994 | |
| Total equity | 4,238 | |
| Interest-bearing borrowings | 1,806 | 0 |
Cash Flow Statement
| Item | 2016 | 2017-07 |
|---|---|---|
| Net cash from operating activities | 21,134 | |
| Net cash from investing activities | -812 | |
| Net cash from financing activities | -21,155 | |
| Net increase in cash | -833 | |
| Depreciation of PP&E | 334 | 256 |
| Purchase of PP&E | -816 | -619 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 9.28 |
|---|---|
| First Day Open | HK$ 9.9 |
| First Day Change | 8.67% |
| First Day Volume | 228624000.0 |
| First Day Turnover | 2239680000.0 |
| Use of Proceeds | 1、約25.0%或702.0百萬港元將用于拓展及升級我們中國網絡的現有輔助生殖醫療機構及招聘醫療專業人士;
2、約20.0%或561.6百萬港元將用于我們目前并無經營的中國省份的額外輔助生殖醫療機構潛在收購;
3、約10.0%或280.8百萬港元將用于投資研發以改善整體表現及維持我們ART的前沿地位;
4、約20.0%或561.6百萬港元將用于輔助生殖服務服務鏈的輔助生殖服務提供商及業務潛在收購;
5、約15.0%或421.2百萬港元將用于改善品牌專注度以及中國及美國對輔助生殖服務的整體專注;
6、約10.0%或280.8百萬港元將用于營運資金及一般企業用途。 |
Underwriting Syndicate
Overall Coordinators (4)
Joint Bookrunners (10)
Morgan Stanley Asia Limited CE AAD291
中信里昂证券有限公司 CE AAB893
Citigroup Global Markets Asia Limited CE AAA137
CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
招银国际融资有限公司 CE AVM940
中信建投(国际)融资有限公司 CE BAU112
农银国际融资有限公司 CE AWL249
ICBC INTERNATIONAL CAPITAL LIMITED CE AQW615
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Mirae Asset Securities (HK) Limited CE BJB333
Joint Lead Managers (10)
Morgan Stanley Asia Limited CE AAD291
中信里昂证券有限公司 CE AAB893
Citigroup Global Markets Asia Limited CE AAA137
CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
招银国际融资有限公司 CE AVM940
中信建投(国际)融资有限公司 CE BAU112
农银国际融资有限公司 CE AWL249
ICBC INTERNATIONAL CAPITAL LIMITED CE AQW615
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Mirae Asset Securities (HK) Limited CE BJB333
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Ally Bridge LB Healthcare Master Fund Limited | 235,174,520 HKD | — | 7.71% | — | 6 months | 2019-12-25 |
| 2 | Cormorant Asset Management, LP | 156,777,320 HKD | — | 5.14% | — | 6 months | 2019-12-25 |
| 3 | Hillhouse Funds | 548,746,240 HKD | — | 17.99% | — | 6 months | 2019-12-25 |
| 4 | Worldwide Healthcare Trust PLC | 235,174,520 HKD | — | 7.71% | — | 6 months | 2019-12-25 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 王彬 | — |
| Company Secretary | 劉竑琨 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | Jinxin Fertility BVI持股21.10%,Amethyst Gem持股18.77%,HRC Investment持股15.15%,Jinxin Global BVI持股5.50%。 |
|---|




